MDS Nordion is partnering with Villepinte, France-based Guerbet and Caen, France-based Cyceron to develop new PET radiotracers for cancer diagnostics.
The project will investigate a radiopharmaceutical using gallium-68 to assess its functionality and image quality, develop a formulation to allow preparation at an imaging clinic and evaluate commercial feasibility, said MDS, which is headquartered in Ottawa, Ontario.
Under the terms of the agreement, MDS, Guerbet and Cyceron will provide complementary expertise in radiochemistry, radiolabeling and targeted delivery of radioisotopes. Guerbet will lead the project for its duration as the scientific coordinator. In addition, each party will provide scientific resources and in-kind contributions for the project.